Is Vaxart Stock a Buy?

Last January, Vaxart (NASDAQ: VXRT) was just a micro cap, investigating a series of oral-tablet vaccines to treat viral infections. Its stock was trading for as little as $0.70. However, over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX).

Perhaps unsurprisingly, the company has its fair share of skeptics. In fact, over 30% of Vaxart stock has been sold short. Many are convinced that Vaxart is a vaccine underdog with a way-too-ambitious candidate and a fair share of administrative problems. Should you give the stock a chance?